INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 18, 2020, covers events related to INVO Bioscience, Inc. (trading symbol: INVO), a Nevada corporation. The report details the completion of a public offering of common stock and the subsequent exercise of an underwriting option.
Key Financial Metrics
- Offering Structure: Public offering of 3,625,000 shares at $3.20 per share, with an additional option for 528,750 shares.
- Total Shares Sold: 4,153,750 shares of Common Stock.
- Net Proceeds: Approximately $11.62 million received by the Company after deducting underwriting discounts, commissions, and offering expenses.
- Option Proceeds: Approximately $1.52 million received from the sale of the 528,750 Option Shares.
- Underwriter: Roth Capital Partners, LLC.
Material Changes
The primary material change is the increase in the Company's cash liquidity due to the successful closing of the public offering and the full exercise of the underwriters' option to purchase additional shares. The initial closing occurred on November 17, 2020, and the option shares closed on November 20, 2020.
Outlook and Management Commentary
The filing confirms the successful execution of the capital raise as previously announced. No specific forward-looking guidance, risk factors, or management commentary regarding future operations is included in this specific 8-K filing beyond the confirmation of the transaction details.
Investor Verification Checklist
- Verify the final share count of 4,153,750 issued in the offering.
- Confirm the net proceeds of approximately $11.62 million against the Company's cash balance in subsequent filings.
- Review the use of proceeds disclosed in the related prospectus or press release.
- Check for any dilution impact on existing shareholders due to the issuance of new common stock.